- Home
- PRG vs NVCR Comparison
PRG vs NVCR Comparison
Compare PRG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | NVCR |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRG | NVCR |
|---|---|---|
| Price | $29.43 | $13.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $37.50 | $28.42 |
| AVG Volume (30 Days) | 605.8K | ★ 1.5M |
| Earning Date | 02-18-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | $642,269,000.00 |
| Revenue This Year | $1.24 | $9.75 |
| Revenue Next Year | $7.02 | $5.62 |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | 3.71 | ★ 11.17 |
| 52 Week Low | $23.50 | $10.70 |
| 52 Week High | $44.43 | $31.17 |
Technical Indicators
Market Signals| Indicator | PRG | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 54.16 |
| Support Level | $30.10 | $12.88 |
| Resistance Level | $30.76 | $13.64 |
| Average True Range (ATR) | 0.68 | 0.47 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 5.88 | 49.70 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.